CorFlow Presents at the ACC.19 Conference in New Orleans

CorFlow Presents ACC Poster on Hemodynamic Instability and the Impact on Microvascular Dysfunction

Baar, Switzerland, March 17th 2019

CorFlow Therapeutics AG today announced that the company will present further findings related to the diagnosis and treatment of coronary microvascular obstruction (MVO) during the annual meeting of the American College of Cardiology (ACC.19) in New Orleans, LA, March 16-18, 2019.

CorFlow has since its foundation in June 2016 worked to document that the Controlled Flow Infusion (CoFITM) technology is able to measure the coronary microvascular status and provide therapy to the compromised coronary microcirculation at the same time. MVO affects more than half of acute heart attack patients and is an independent predictor for complications including acute and late heart failure which constitutes a high cost burden for the world-wide health care system. To address this large unmet medical need, CorFlow has developed an in-vivo model which reproducibly creates MVO in an occlusion-reperfusion model with very low complication rates. Using this in-vivo model, the CoFITM technology was used to measure real-time dynamic microvascular resistance (dMVR) in the coronary circulation and these dMVR values have been correlated to post-procedure contrast enhanced magnetic resonance imaging (cMRI) and histology. A correlation between the procedural CoFITM dMVR values and post-procedural MRI will enable treatment of MVO before the patients leave the cathlab and potentially reduce the complication rates for severe heart attack patients.

In a comment, Dr. Robert S. Schwartz, the first author of the publication and co-Founder of CorFlow Therapeutics, stated: “We continue to discover how impactful the CoFITM diagnostic sequence is to characterise the coronary microcirculation. Our findings show the we can quantify the microvascular collapse which occurs in heart attack patients and that this collapse has direct implications on the hemodynamic instability seen in these patients. We believe that this understanding will have important implications on how we manage microvascular dysfunction in clinical syndromes such as STEMI/NSTEMI, cardiogenic shock, no-reflow, and stress cardiomyopathy.”

CorFlow’s development is supported in part through a public grant awarded by Innosuisse, the Swiss Innovation Agency, and conducted in cooperation with the University of Bern (ARTORG), the University Hospital of Zürich (Dept. of Cardiology and Div. of Surgical Research), the University of Applied Science Buchs NTB, the University Hospital in Bern (Inselspital) and the Swiss Federal Institutes of Technology (ETH) in Zürich, Switzerland.

The poster “Coronary Microvascular Dysfunction Is Induced by Hemodynamic Instability: Quantitation by Controlled Flow Infusion” describes the recent findings from the CorFlow in-vivo model. The poster will be presented on Monday March 18th (poster session 1304, Hall F).

Jon H. Hoem, CorFlow’s CEO and co-Founder, commented: “We are very pleased that we continue to expand our understanding of the CoFI technology and look forward to convert this understanding to clinical value for all the patients needing improved coronary care.”

The data from the CorFlow non-clinical trials have been used in the regulatory submissions for the upcoming CorFlow MOCA (MVO with CoFI™ System Assessment) First-in-Man clinical trial.

The American College of Cardiology (ACC) mission is to transform cardiovascular care and improve heart care. ACC seeks to reach this mission through its members so that they may dramatically reduce the incidence, severity, and complications of cardio-vascular disease through promoting prevention, reduction of disparities in health care and improve personal population-based cardiovascular health.

ACC publishes several well recognised peer-reviewed journals (JACC) with a wide distribution in the inter-ventional cardiology community.

These clinical trials have documented that around half of all acute heart attack patients have MVO as documented by Magnetic Resonance Imaging (MRI). This translates into around 200,000 patients per year and 25% of these patients will be in heart failure after four years. MVO is therefore a major contributor to the rising costs for taking care of heart failure patients.

The 68th annual meeting of ACC will this year be held in New Orleans (LA). Last year’s event was attended by more than 16,600 attendees from 108 countries and hosted 273 exhibitors.

Share this post

Leave a Reply

Your email address will not be published. Required fields are marked *

six + sixteen =